NAFLD and liver transplantation: Current burden and expected challenges

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1245-1257

  Pais, Raluca ^a,b   Barritt, A Sidney ^c   Calmus, Yvon ^a,b   Scatton, Olivier ^a   Runge, Thomas ^c   Lebray, Pascal ^a   Poynard, Thierry ^a,b   Ratziu, Vlad ^a,b   Conti, Filomena ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Fatty liver; Liver transplantation; Steatohepatitis

Indexed keywords

CHRONIC LIVER DISEASE; CLINICAL OUTCOME; COMORBIDITY ASSESSMENT; END STAGE LIVER DISEASE; EUROPE; HEALTH CARE ACCESS; HOSPITAL ADMISSION; HUMAN; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; ORGAN DONOR; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; UNITED STATES; VASCULAR DISEASE; LIVER TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; EUROPE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 85003881532     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.033     Document Type: Review

References (149)

1. [1] Ludwig, J., Viggiano, T.R., McGill, D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
2. [2] Ekstedt, M., Franzen, L.E., Mathiesen, U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
3. [3] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
4. [4] Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
5. [5] Kotronen, A., Yki-Jarvinen, H., Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28 (2008), 27–38.
6. [6] Leite, N.C., Salles, G.F., Araujo, A.L., et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29 (2009), 113–119.
7. [7] Adams, L.A., Waters, O.R., Knuiman, M.W., et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104 (2009), 861–867.
8. [8] Younossi, Z.M., Stepanova, M., Afendy, M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 9, 2011 524–530.e1. quiz e60.
9. [9] Clark, J., The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003), 960–967.
10. [10] Ioannou, G.N., Weiss, N.S., Boyko, E.J., et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43 (2006), 1145–1151.
11. [11] Lazo, M., Clark, J.M., The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28 (2008), 339–350.
12. [12] Armstrong, M.J., Houlihan, D.D., Bentham, L., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 56 (2012), 234–240.
13. [13] Bedogni, G., Miglioli, L., Masutti, F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005), 44–52.
14. [14] Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
15. [15] Das, K., Das, K., Mukherjee, P.S., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51 (2010), 1593–1602.
16. [16] Farrell, G.C., Wong, V.W., Chitturi, S., NAFLD in Asia–as common and important as in the West. Nat Rev Gastroenterol Hepatol 10 (2013), 307–318.
17. [17] Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
18. [18] Lazo, M., Hernaez, R., Eberhardt, M.S., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 178 (2013), 38–45.
19. [19] Ratziu, V., Voiculescu, M., Poynard, T., Touching some firm ground in the epidemiology of NASH. J Hepatol 56 (2012), 23–25.
20. [20] Wong, R.J., Aguilar, M., Cheung, R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
21. [21] Kim, W.R., Lake, J.R., Smith, J.M., et al. OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant 15 (2015), 1–28.
22. [22] Adam, R., Karam, V., Delvart, V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57 (2012), 675–688.
23. [23] Charlton, M.R., Burns, J.M., Pedersen, R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 (2011), 1249–1253.
24. [24] Caldwell, S.H., Oelsner, D.H., Iezzoni, J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999), 664–669.
25. [25] Greeve, M., Ferrell, L., Kim, M., et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology 17 (1993), 593–598.
26. [26] Powell, E.E., Cooksley, W.G.E., Hanson, R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990), 74–80.
27. [27] Poonawala, A., Nair, S.P., Thuluvath, P.J., Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 (2000), 689–692.
28. [28] Ayata, G., Gordon, F.D., Lewis, W.D., et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 33 (2002), 1098–1104.
29. [29] Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
30. [30] Younossi, Z.M., Gramlich, T., Bacon, B.R., et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30 (1999), 847–850.
31. [31] Ratziu, V., Bonyhay, L., Di Martino, V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002), 1485–1493.
32. [32] Bhala, N., Angulo, P., van der Poorten, D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54 (2011), 1208–1216.
33. [33] Sanyal, A.J., Banas, C., Sargeant, C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43 (2006), 682–689.
34. [34] Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
35. [35] Bugianesi, E., Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002), 134–140.
36. [36] Marrero, J.A., Fontana, R.J., Fu, S., et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42 (2005), 218–224.
37. [37] Nair, S., Mason, A., Eason, J., et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 36 (2002), 150–155.
38. [38] Hassan, M.M., Curley, S.A., Li, D., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116 (2010), 1938–1946.
39. [39] Ascha, M.S., Hanouneh, I.A., Lopez, R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51 (2010), 1972–1978.
40. [40] Pais, R., Lebray, P., Rousseau, G., et al. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants. Clin Gastroenterol Hepatol, 13, 2015 992–9.e2.
41. [41] Younossi, Z.M., Otgonsuren, M., Henry, L., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
42. [42] Dyson, J., Jaques, B., Chattopadyhay, D., et al. Hepatocellular cancer – the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
43. [43] Mittal, S., Sada, Y.H., El-Serag, H.B., et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol, 13, 2015 594–601.e1.
44. [44] Piscaglia, F., Svegliati-Baroni, G., Barchetti, A., et al. Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatology 63 (2016), 827–838.
45. [45] EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 57 (2012), 399–420.
46. [46] Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 (2014), 2188–2195.
47. [47] Singal, A.K., Salameh, H., Kuo, Y.F., et al. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 98 (2014), 216–221.
48. [48] Singhal, A., Wilson, G.C., Wima, K., et al. Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int 28 (2015), 148–155.
49. [49] O'Leary, J.G., Landaverde, C., Jennings, L., et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol, 9, 2011 700–704.e1.
50. [50] Stine, J.G., Shah, N.L., Argo, C.K., et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). Liver Transpl 21 (2015), 1016–1021.
51. [51] Tripodi, A., Fracanzani, A.L., Primignani, M., et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 61 (2014), 148–154.
52. [52] Englesbe, M.J., Schaubel, D.E., Cai, S., et al. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 16 (2010), 999–1005.
53. [53] Francoz, C., Valla, D., Durand, F., Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 57 (2012), 203–212.
54. [54] Parikh, N.D., Hutton, D., Marrero, W., et al. Projections in donor organs available for liver transplantation in the United States: 2014–2025. Liver Transpl 21 (2015), 855–863.
55. [55] Orman, E.S., Barritt, A.St., Wheeler, S.B., et al. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl 19 (2013), 59–68.
56. [56] Orman, E.S., Mayorga, M.E., Wheeler, S.B., et al. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl 21 (2015), 1040–1050.
57. [57] Minervini, M.I., Ruppert, K., Fontes, P., et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 50 (2009), 501–510.
58. [58] Jun, M.J., Shim, J.H., Kim, S.Y., et al. Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation. Liver Transpl 20 (2014), 437–445.
59. [59] Ahn, J.S., Sinn, D.H., Gwak, G.Y., et al. Steatosis among living liver donors without evidence of fatty liver on ultrasonography: potential implications for preoperative liver biopsy. Transplantation 95 (2013), 1404–1409.
60. [60] Rogier, J., Roullet, S., Cornelis, F., et al. Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio. Liver Transpl 21 (2015), 690–695.
61. [61] Abu-Amara, M., Yang, S.Y., Tapuria, N., et al. Liver ischemia/reperfusion injury: processes in inflammatory networks–a review. Liver Transpl 16 (2010), 1016–1032.
62. [62] Han, S., Ha, S.Y., Park, C.K., et al. Microsteatosis may not interact with macrosteatosis in living donor liver transplantation. J Hepatol 62 (2015), 556–562.
63. [63] McCormack, L., Dutkowski, P., El-Badry, A.M., et al. Liver transplantation using fatty livers: always feasible?. J Hepatol 54 (2011), 1055–1062.
64. [64] Spitzer, A.L., Lao, O.B., Dick, A.A., et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 16 (2010), 874–884.
65. [65] Wong, T.C., Fung, J.Y., Chok, K.S., et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. Liver Transpl 22 (2016), 226–236.
66. [66] Bejaoui, M., Pantazi, E., Folch-Puy, E., et al. Emerging concepts in liver graft preservation. World J Gastroenterol 21 (2015), 396–407.
67. [67] Compagnon, P., Lindell, S., Ametani, M.S., et al. Ischemic preconditioning and liver tolerance to warm or cold ischemia: experimental studies in large animals. Transplantation 79 (2005), 1393–1400.
68. [68] Weeder, P.D., van Rijn, R., Porte, R.J., Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: rationale, current evidence and future directions. J Hepatol 63 (2015), 265–275.
69. [69] Nagrath, D., Xu, H., Tanimura, Y., et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng 11 (2009), 274–283.
70. [70] Compagnon, P., Clement, B., Campion, J.P., et al. Effects of hypothermic machine perfusion on rat liver function depending on the route of perfusion. Transplantation 72 (2001), 606–614.
71. [71] Dutkowski, P., Schlegel, A., de Oliveira, M., et al. HOPE for human liver grafts obtained from donors after cardiac death. J Hepatol 60 (2014), 765–772.
72. [72] Tandoi, F., Salizzoni, M., Brunati, A., et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. Liver Transpl 22 (2016), 377–378.
73. [73] Leonard, J., Heimbach, J.K., Malinchoc, M., et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 8 (2008), 667–672.
74. [74] Pelletier, S.J., Schaubel, D.E., Wei, G., et al. Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl 13 (2007), 1678–1683.
75. [75] Pelletier, S.J., Maraschio, M.A., Schaubel, D.E., et al. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transpl, 2003, 77–88.
76. [76] Dick, A.A., Spitzer, A.L., Seifert, C.F., et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 15 (2009), 968–977.
77. [77] Nair, S., Verma, S., Thuluvath, P.J., Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 35 (2002), 105–109.
78. [78] Dare, A.J., Plank, L.D., Phillips, A.R., et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. Liver Transpl 20 (2014), 281–290.
79. [79] Hakeem, A.R., Cockbain, A.J., Raza, S.S., et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. Liver Transpl 19 (2013), 551–562.
80. [80] Nair, S., Cohen, D.B., Cohen, M.P., et al. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 96 (2001), 842–845.
81. [81] Agopian, V.G., Kaldas, F.M., Hong, J.C., et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 256 (2012), 624–633.
82. [82] Malik, S.M., Devera, M.E., Fontes, P., et al. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 15 (2009), 1843–1851.
83. [83] Yalamanchili, K., Saadeh, S., Klintmalm, G.B., et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 16 (2010), 431–439.
84. [84] Bhagat, V., Mindikoglu, A.L., Nudo, C.G., et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 15 (2009), 1814–1820.
85. [85] Barritt, A.St., Dellon, E.S., Kozlowski, T., et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol 45 (2011), 372–378.
86. [86] Houlihan, D.D., Armstrong, M.J., Davidov, Y., et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?. Liver Transpl 17 (2011), 1292–1298.
87. [87] Park, C.W., Tsai, N.T., Wong, L.L., Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 25 (2011), E606–E611.
88. [88] Reddy, S.K., Steel, J.L., Chen, H.W., et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 55 (2012), 1809–1819.
89. [89] Vanwagner, L.B., Bhave, M., Te, H.S., et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 56 (2012), 1741–1750.
90. [90] Kennedy, C., Redden, D., Gray, S., et al. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford) 14 (2012), 625–634.
91. [91] Afzali, A., Berry, K., Ioannou, G.N., Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 18 (2012), 29–37.
92. [92] Wang, X., Li, J., Riaz, D.R., et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 12, 2014 394–402.e1.
93. [93] Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
94. [94] Soderberg, C., Stal, P., Askling, J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51 (2010), 595–602.
95. [95] Johnston, S.D., Morris, J.K., Cramb, R., et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73 (2002), 901–906.
96. [96] Neal, D.A., Tom, B.D., Luan, J., et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant?. Transplantation 77 (2004), 93–99.
97. [97] Watt, K.D., Pedersen, R.A., Kremers, W.K., et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 10 (2010), 1420–1427.
98. [98] Fussner, L.A., Heimbach, J.K., Fan, C., et al. Cardiovascular disease after liver transplantation. When, what and who is at risk. Liver Transpl 21 (2015), 889–896.
99. [99] Newsome, P.N., Allison, M.E., Andrews, P.A., et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 61 (2012), 484–500.
100. [100] Richards, J., Gunson, B., Johnson, J., et al. Weight gain and obesity after liver transplantation. Transpl Int 18 (2005), 461–466.
101. [101] Choudhary, N.S., Saigal, S., Saraf, N., et al. Sarcopenic obesity with metabolic syndrome: a newly recognized entity following living donor liver transplantation. Clin Transplant 29 (2015), 211–215.
102. [102] Hong, H.C., Hwang, S.Y., Choi, H.Y., et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 59 (2014), 1772–1778.
103. [103] Bianchi, G., Marchesini, G., Marzocchi, R., et al. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 14 (2008), 1648–1654.
104. [104] Heisel, O., Heisel, R., Balshaw, R., et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4 (2004), 583–595.
105. [105] Pagadala, M., Dasarathy, S., Eghtesad, B., et al. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 15 (2009), 1662–1670.
106. [106] Watt, K.D., Charlton, M.R., Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 53 (2010), 199–206.
107. [107] Watt, K.D., Metabolic syndrome: is immunosuppression to blame?. Liver Transpl 17 (2011), S38–S42.
108. [108] Charlton, M., Kasparova, P., Weston, S., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7 (2001), 608–614.
109. [109] Contos, M.J., Cales, W., Sterling, R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001), 363–373.
110. [110] Ong, J., Younossi, Z.M., Reddy, V., et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7 (2001), 797–801.
111. [111] Dureja, P., Mellinger, J., Agni, R., et al. NAFLD recurrence in liver transplant recipients. Transplantation 91 (2011), 684–689.
112. [112] El Atrache, M.M., Abouljoud, M.S., Divine, G., et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant 26 (2012), E505–E512.
113. [113] Dumortier, J., Giostra, E., Belbouab, S., et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 105 (2010), 613–620.
114. [114] Seo, S., Maganti, K., Khehra, M., et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 13 (2007), 844–847.
115. [115] Kim, H., Lee, K., Lee, K.W., et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant 28 (2014), 521–529.
116. [116] Finkenstedt, A., Auer, C., Glodny, B., et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 11 (2013), 1667–1672.
117. [117] Watt, K.D., Dierkhising, R., Fan, C., et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant 13 (2013), 2450–2457.
118. [118] Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol, 13, 2015 643–654.e9.
119. [119] Vallin, M., Guillaud, O., Boillot, O., et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. Liver Transpl 20 (2014), 1064–1071.
120. [120] Cusi, K., Chang, Z., Harrison, S., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60 (2014), 167–174.
121. [121] Ratziu, V., Charlotte, F., Bernhardt, C., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
122. [122] Aithal, G.P., Thomas, J.A., Kaye, P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 (2008), 1176–1184.
123. [123] Lippman, S.M., Klein, E.A., Goodman, P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2009), 39–51.
124. [124] Schurks, M., Glynn, R.J., Rist, P.M., et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ, 341, 2010, c5702.
125. [125] Bjelakovic, G., Nikolova, D., Simonetti, R.G., et al. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev, 2008, Cd004183.
126. [126] Ratziu, V., Goodman, Z., Sanyal, A., Current efforts and trends in the treatment of NASH. J Hepatol 62 (2015), S65–S75.
127. [127] EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64 (2016), 433–485.
128. [128] Martin, P., DiMartini, A., Feng, S., et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59 (2014), 1144–1165.
129. [129] Halegoua-De Marzio, D.L., Wong, S.Y., Fenkel, J.M., et al. Listing practices for morbidly obese patients at liver transplantation centers in the United States. Exp Clin Transplant, 2016.
130. [130] Promrat, K., Kleiner, D.E., Niemeier, H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (2010), 121–129.
131. [131] Sacks, F.M., Bray, G.A., Carey, V.J., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360 (2009), 859–873.
132. [132] Debette-Gratien, M., Tabouret, T., Antonini, M.T., et al. Personalized adapted physical activity before liver transplantation: acceptability and results. Transplantation 99 (2015), 145–150.
133. [133] Berzigotti, A., Albillos, A., Villanueva, C., et al. Lifestyle intervention by a 16-week programme of supervised diet and physical exercise ameliorates portal hypertension in patients with cirrhosis and obesity-the SportDiet study. Hepatology, 60, 2014, 253A.
134. [134] Lassailly, G., Caiazzo, R., Buob, D., et al. Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149 (2015), 379–388.
135. [135] Mosko, J.D., Nguyen, G.C., Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 9 (2011), 897–901.
136. [136] Heimbach, J.K., Watt, K.D., Poterucha, J.J., et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 13 (2013), 363–368.
137. [137] Lazzati, A., Iannelli, A., Schneck, A.S., et al. Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery. Obes Surg 25 (2015), 134–142.
138. [138] Yoo, H.Y., Thuluvath, P.J., The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 74 (2002), 1007–1012.
139. [139] Francque, S.M., van der Graaff, D., Kwanten, W.J., Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol 65 (2016), 425–443.
140. [140] Pais, R., Giral, P., Khan, J.F., et al. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 65 (2016), 95–102.
141. [141] Azarbal, B., Poommipanit, P., Arbit, B., et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl 17 (2011), 809–813.
142. [142] Marui, A., Kimura, T., Tanaka, S., et al. Coronary revascularization in patients with liver cirrhosis. Ann Thorac Surg 91 (2011), 1393–1399.
143. [143] Robinson, L.R., Switala, J., Tarter, R.E., et al. Functional outcome after liver transplantation: a preliminary report. Arch Phys Med Rehabil 71 (1990), 426–427.
144. [144] Aadahl, M., Hansen, B.A., Kirkegaard, P., et al. Fatigue and physical function after orthotopic liver transplantation. Liver Transpl 8 (2002), 251–259.
145. [145] Didsbury, M., McGee, R.G., Tong, A., et al. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis. Transplantation 95 (2013), 679–687.
146. [146] Krasnoff, J.B., Vintro, A.Q., Ascher, N.L., et al. A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant 6 (2006), 1896–1905.
147. [147] Roske, A.E., Plauth, M., Liver transplantation, body composition, and substrate utilization: does organ transplantation normalize the metabolic situation of the patient?. Nutrition 15 (1999), 504–505.
148. [148] Langer, G., Grossmann, K., Fleischer, S., et al. Nutritional interventions for liver-transplanted patients. Cochrane Database Syst Rev, 2012, Cd007605.
149. [149] Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63 (2014), 2985–3023.